Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated Outlines Company’s plans to initiate market expansion study (“POC 2”) into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025 Access the “What This Means” video here THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medic ...

Figure: 1 Pancreatic Cancer Pain PoC 1 STUDY Initial trial phase (“PoC 1”) achieved key learnings and met all study objectives Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and 73% of responders remaining opioid free at 4-6 week follow-up Company has initiated market expansion study (“PoC 2”) of additional visceral cancers, and earlier stage pancreatic cancer, to begin in Q2 2025 Additional indications potentially double the addressable ...

New patent underscores breadth of application and expansion opportunities for Company's catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, April 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, t ...

Core Viewpoint - Autonomix Medical, Inc. is preparing to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval of its innovative medical technology aimed at diagnosing and treating diseases of the nervous system [1][3]. Company Overview - Autonomix Medical, Inc. is focused on advancing technologies for the diagnosis and treatment of nervous system diseases, featuring a first-in-class platform system technology that includes a catheter-based microchip sensing array [4]. - The technology is designed to detect and differentiate neural signals with up to 3,000 times greater sensitivity than existing technologies, enabling transvascular diagnosis and treatment of peripheral nervous system diseases [4]. Clinical Development - The company is initially developing its technology for pain treatment, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5]. - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management [5]. Expert Engagement - Autonomix has engaged a team of U.S. and international medical experts in interventional radiology and cancer pain to guide its clinical and regulatory path, ensuring that pre-clinical and clinical studies align with the needs for the FDA De Novo submission expected in 2026 [1][2][3].

THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO), being held April 13-16, 2025 in Rotterdam, Netherlands. Details of the poster presentation are as fol ...

Company Overview - Autonomix Medical, Inc. is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which may detect and differentiate neural signals with approximately 3,000 times greater sensitivity than current technologies [3] - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] Stock Option Grant - The Compensation Committee of Autonomix's Board of Directors approved an inducement stock option grant on March 17, 2025, for a new non-executive employee to purchase 7,500 shares of common stock [1] - The exercise price of the options is equal to the closing price of Autonomix's common stock on the grant date, and the options have a ten-year term, vesting in four equal annual installments [2]

Core Insights - Autonomix Medical, Inc. has made significant advancements in its patent portfolio, now holding over 80 issued patents and 40 pending applications, which strengthens its proprietary technology in the medical device sector [1][5] - The company’s proprietary sensing and ablation technology shows promise in precisely targeting and eliminating overactive nerves, which could enhance patient outcomes across various medical conditions [1][3] Patent and Technology Developments - The United States Patent and Trademark Office has issued U.S. patent 12,217,863, which protects Autonomix's technology for capturing and processing physiological signals, applicable in heart mapping, arterial mapping, and central nervous system monitoring [1][4] - The technology platform utilizes a catheter-based microchip sensing array that can detect neural signals with up to 3,000 times greater sensitivity than existing technologies, enabling a more effective approach to treating chronic pain and other conditions [3][5] Clinical Applications and Future Plans - Autonomix is initially focusing on the treatment of pancreatic cancer pain, with plans to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 [4][6] - The technology has potential applications beyond cancer pain, including conditions related to hypertension and chronic pain management, indicating a broad spectrum of future indications [2][6]

Core Insights - Autonomix Medical, Inc. has made significant advancements in its patent portfolio, now holding over 80 issued patents and 40 pending applications, which strengthens its proprietary technology in the medical device sector [1][2] - The company’s proprietary sensing and ablation technology shows promise in precisely targeting and eliminating overactive nerves, which could enhance patient outcomes across various medical conditions [1][3] Patent and Technology Development - The United States Patent and Trademark Office has issued U.S. patent 12,217,863, which protects Autonomix's technology for capturing and processing physiological signals, applicable in heart mapping, arterial mapping, and central nervous system monitoring [1][4] - The technology platform utilizes a catheter-based microchip sensing array antenna that can detect neural signals with up to 3,000 times greater sensitivity than existing technologies, enabling a more effective treatment approach [3][5] Clinical Applications and Future Plans - Autonomix is initially focusing on the treatment of pancreatic cancer pain, with plans to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 [4][6] - The technology has potential applications beyond cancer pain, including conditions related to hypertension and chronic pain management, indicating a broad spectrum of future indications [2][6]

Core Insights - Autonomix Medical, Inc. has successfully completed the design lock for its Apex 6 Radiofrequency Generator, integrating enhancements into a fully integrated transvascular treatment platform named the Autonomix Sensing and RF Ablation System, which is on track for Investigational Device Exemption submission and potential U.S. clinical trial initiation in 2025 for pancreatic cancer pain [1][4] Group 1: Company Developments - The integration of the Apex 6 Generator into the Autonomix platform allows for a cost-effective and de-risked approach to accelerate development, following a transaction with RF Innovations, Inc. to license the intellectual property [2] - The company is collaborating with RF Innovations' manufacturing partner to facilitate equipment development, enhancing its manufacturing supply chain [3] Group 2: Market Need and Technology - There is a significant need to transform treatment for pancreatic cancer patients, focusing on effective pain relief and improved quality of life, with early clinical results indicating potential to address this unmet medical need [3] - The technology includes a catheter-based microchip sensing array capable of detecting neural signals with approximately 3,000 times greater sensitivity than current technologies, enabling transvascular diagnosis and treatment of peripheral nervous system diseases [5][6] Group 3: Future Plans - The company plans to submit an IDE and commence U.S. clinical trials in 2025 to support commercialization of the Autonomix Sensing and RF Ablation System for pancreatic cancer pain [4]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [4] - The company's first-in-class platform technology includes a catheter-based microchip sensing array that detects neural signals with approximately 3,000 times greater sensitivity than current technologies [4] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases [4] Technology Development - Initial development of the technology is targeted at pain treatment, specifically for pancreatic cancer, which causes severe pain and lacks reliable treatment options [5] - The technology has the potential to address various indications, including cardiology, hypertension, and chronic pain management [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5] Industry Engagement - Autonomix's abstract has been accepted for poster presentation at the 2025 Society of Interventional Radiology Annual Scientific Meeting, scheduled for March 29-April 2, 2025 [1][2] - The Society of Interventional Radiology represents over 8,000 professionals dedicated to improving patient care through image-guided therapies [2] - The annual meeting will focus on emerging methodologies, groundbreaking research, and networking opportunities within the interventional radiology field [2][3] Presentation Details - The presentation titled "Pain Mitigation in Pancreatic Adenocarcinoma: An Interim Analysis of Neurolysis via Transvascular RF Energy-Based Ablation" will be delivered by Dr. Bela Kis on March 31, 2025, from 12:10 PM to 1:10 PM CT [9]